DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for osteogenesis imperfecta — screening already-approved drugs against its 33-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleOsteogenesis imperfecta maps to a 33-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for osteogenesis imperfecta is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
bone morphogenetic protein 1 (BMP1) — BMP1 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet acedrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 3EDH · 1.25 Å · ligand ACETYL GROUP (ACE). Experimental structure, not a prediction.
What the evidence adds up to
Seventy percent of published articles on the medical treatment of osteogenesis imperfecta up to 1981 claimed beneficial results for 20 different agents, yet no form of treatment had been accepted as effective. The 1981 review states that no agent was available that would be of any value to a practitioner treating a patient with osteogenesis imperfecta, and that a high degree of skepticism toward positive results was essential regardless of the source.
A 1997 cross-sectional study of 61 children with osteogenesis imperfecta measured functional outcome using the Dutch translation of the Pediatric Evaluation of Disability Inventory, which assesses capability and performance in self-care, mobility, and social function. Functional abilities, especially in mobility, were related to disease subtype: the more severe the disease, the lower the mobility score. In children aged 7.5 years or younger, self-care scores for all children were within two standard deviations of the median, and despite severe disablement, children with type III scored within normal ranges. In older children, the relationship between subtype and functional ability became more pronounced, and there was a non-significant tendency for social function to be better developed in the most severely disabled children.
A 2013 review notes that osteogenesis imperfecta was historically considered a collagen-related condition predominantly due to mutations in genes encoding the alpha chains of collagen type I, but mutations in various noncollagenous genes have more recently been discovered to cause some rare, recessive forms. The review discusses pathophysiology in relation to these recessive forms but does not report any new treatment results or survival data.
What is still missing is any adequately documented treatment shown to be effective in controlled trials, as well as prospective multicenter studies that could define a disease-related functional ability profile and account for the heterogeneity of subtypes and genetic causes. No drug therapy is supported by the evidence presented.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Clinical Orthopaedics and Related Research · 1981 · 40 citations
Systemic Treatment of Osteogenesis Imperfecta
AbstractSeventy percent of published articles on the medical treatment of osteogenesis imperfecta have claimed beneficial results for 20 different agents. This observation conflicts with current practice since no form of treatment has been accepted as effective in dealing with the disease. A few medications or combinations of medications hold some promise, but adequate documentation must be availble before they can be accurately assessed. It is essential that the practitioner maintain a high degree of skepticism toward positive results of treatment regardless of the source. At the present time, no agent is available which will be of any value to the practitioner who has a patient with osteogenesis imperfecta.
AbstractThe purpose of this study was to determine if the severity of osteogenesis imperfecta (Ol) in childhood might have any influence on functional outcome. In a cross-sectional study, the functional outcome of 61 children with Ol was related to the three subtypes of the disease. Functional outcome was measured with the Dutch translation of the Pediatric Evaluation of Disability Inventory (PEDI). The PEDI measures capability and performance in three specific categories: “self-care, ” “mobility, ” and “social function.” We concluded that functional abilities, especially in the mobility category, were related to Ol subtype. The more severe the disease, the lower the score on mobility. In the self-care area, the score of all children ≤7.5 years of age, was within two standard deviations of the median. Despite severe disablement, children with Ol type III scored within the normal ranges. In older children with Ol, the relationship between Ol subtypes and functional ability became more pronounced. In children with the most severe disablement, there was a tendency, although not significant, for social function to be better developed. In children with a disease such as Ol, which affects posture, alignment, and growth, a severity-related functional ability profile seems to exist. Future multicenter research could further define a disease-related functional ability profile in Ol.
AbstractThis article discusses the pathophysiology of osteogenesis imperfecta (OI), in particular in relation to some rare, recessive forms of the condition. Although historically considered a collagen-related condition, predominantly due to mutations in genes that encode the alpha chains of collagen type I, mutations in various noncollagenous genes have also more recently been discovered to cause some forms of OI.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
